Lineage Cell Therapeutics, Inc.
LCTXNYSECIK 876343HealthcareFiscal year ends Dec 31
Reports and events: 621 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0616:16 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-338064 |
| 2026-08-0616:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338020 |
| 2026-06-1216:32 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events | 0001193125-26-269557 |
| 2026-05-1216:15 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-219479 |
| 2026-05-1216:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219421 |
| 2026-04-2916:10 ET | DEF 14A | Proxy statementPeriod 2026-04-29 | 0001193125-26-191556 |
| 2026-03-1109:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-101167 |
| 2026-03-0516:16 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-093992 |
| 2026-03-0516:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-093948 |
| 2025-11-2816:05 ET | 8-K | 8.01 Other events | 0001193125-25-302552 |
| 2025-11-2406:49 ET | 8-K | 8.01 Other events | 0001193125-25-291979 |
| 2025-11-1418:12 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000919574-25-007051 |
| 2025-11-1209:25 ET | 8-K | 8.01 Other events | 0001193125-25-276249 |
| 2025-11-0616:18 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-269599 |
| 2025-11-0616:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-269534 |
| 2025-08-2609:14 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-111319 |
| 2025-08-1216:16 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-107333 |
| 2025-08-1216:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-107314 |
| 2025-07-0216:25 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-093007 |
| 2025-06-2309:26 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-088738 |
| 2025-06-0917:25 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0000950170-25-083866 |
| 2025-05-1316:15 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-070378 |
| 2025-05-1316:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-070337 |
| 2025-05-0109:09 ET | 8-K | 8.01 Other events | 0000950170-25-061466 |
| 2025-04-2916:05 ET | DEF 14A | Proxy statementPeriod 2025-06-26 | 0000950170-25-060090 |
| 2025-03-1016:15 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-036309 |
| 2025-03-1016:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-036278 |
| 2025-01-2820:07 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000919574-25-000556 |
| 2025-01-2716:30 ET | 8-K | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-009227 |
| 2024-12-0916:30 ET | DEF 14A | Proxy statementPeriod 2024-12-09 | 0000950170-24-134577 |
| 2024-11-2120:05 ET | SC 13D/A | Ownership report, active investor, amended | 0000919574-24-006855 |
| 2024-11-2017:08 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-129402 |
| 2024-11-1416:15 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-127077 |
| 2024-11-1416:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-127058 |
| 2024-08-0816:15 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-094004 |
| 2024-08-0816:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093947 |
| 2024-06-1417:00 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0000950170-24-073769 |
| 2024-06-1316:30 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-24-073072 |
| 2024-05-1416:39 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-059689 |
| 2024-05-0916:15 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-056998 |
| 2024-05-0916:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056948 |
| 2024-04-2916:30 ET | DEF 14A | Proxy statementPeriod 2024-06-11 | 0000950170-24-049935 |
| 2024-03-2216:15 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-035365 |
| 2024-03-0716:21 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-027988 |
| 2024-03-0716:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-027951 |
| 2024-02-1517:27 ET | 8-K | 8.01 Other events | 0001493152-24-006901 |
| 2024-02-0818:57 ET | SC 13D/A | Ownership report, active investor, amended | 0000919574-24-000756 |
| 2024-02-0609:20 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-24-005046 |
| 2023-11-0916:15 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001493152-23-040058 |
| 2023-11-0916:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-23-040057 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.